Indivumed and the Oslo University Hospital's Institute for Cancer Genetics and Informatics will develop algorithms to automate colorectal cancer prognoses.
News items for the week of May 3, 2021.
Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor.
This is MHRA's first authorization under Project Orbis, an international regulatory collaboration the UK body joined in January to speed access to drugs.
GE intends to scale access to the PET imaging agent so at least 75 percent of metastatic breast cancer patients in the US have access to it by 2023.
The companies will conduct a Phase I/II clinical trial to evaluate Fusion's FPI-1434 and Merck's checkpoint inhibitor in solid tumors expressing IGF-1R.
The deal is worth $296 million, with SpringWorks paying $11 million upfront and up to $285 million upon reaching certain milestones.
The agency granted accelerated approval to Merck's pembrolizumab plus Herceptin and chemotherapy for patients with advanced, HER2-positive gastric cancer.
The trial will include patients with mesothelioma and solid tumors that have progressed on standard treatments and harbor an NF2 mutation.
UK-based Alchemab will use its platform to sequence the antibody repertoires of prostate cancer patients treated within an AstraZeneca immunotherapy trial.